Pateclizumab Biosimilar

REQUEST MORE INFO
Catalogue No: abx831229
Price: US$435.00
(Size: 100 µg)

Orders to United States ship from United States

Click on the image to see the image legend

Available Options

* Size:




Add to Cart Buy It Now GET A QUOTE

Documents

Datasheet SDS
Pateclizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting LTA/TNFSF1, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis).

Target LTA/TNFSF1
Research Area Humanized Monoclonal Antibodies, Biosimilars
Clonality Monoclonal
Reactivity Human
Expression Recombinant
Tested Applications ELISA
Host Human
Recommended dilutions Optimal dilutions/concentrations should be determined by the end user.
Conjugation Unconjugated
Isotype IgG1 Kappa
Form Liquid
Purity > 95%
Purification Purified from cell culture supernatants by Protein A/G chromatography.
Storage Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life 12 months.
Buffer 0.01 M PBS, pH 7.4.
CAS Number 1202526-59-7
Concentration Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability Shipped within 5-10 working days.
Note THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Research Articles on LTA/TNFSF1


Write a review

Tags:
(Click to show)